Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 crawled time : 12:30 save search
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
Published: 2022-03-24 (Crawled : 12:30) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: -0.1%
H: 0.0%
C: 0.0%
conference therapeutics preclinical international cudetaxestat phase 1 pre-clinical
Surrozen Reports Fourth Quarter and Full Year 2021 Financial ResultsOn Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022
Published: 2022-03-24 (Crawled : 12:30) - biospace.com/
SRZN | $9.01 7.7K
|
|
| O: -2.59%
H: 10.03%
C: -3.54%
szn-1326 trials phase 1
Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
Published: 2022-03-22 (Crawled : 12:30) - biospace.com/
PSTV | News | $1.55 -4.91% 4.9K
|
Health Technology
|
| O: -0.99%
H: 10.0%
C: 0.0%
trial therapeutics phase 1
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Published: 2022-03-15 (Crawled : 12:30) - biospace.com/
ARWR | $23.05 -3.07% 220K
|
Health Technology
|
| O: 1.89%
H: 2.65%
C: 0.87%
treatment clearance phase 1 phase 2
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
LCTX | $1.115 -2.19% 370K
|
Health Technology
|
| O: -8.45%
H: 0.0%
C: 0.0%
rg6501 opregen research presentation phase 1 results
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
Published: 2022-03-07 (Crawled : 12:30) - biospace.com/
RPTX 4 | $3.355 -0.15% 17K
|
Health Technology
|
| O: -5.48%
H: 5.02%
C: 1.56%
rp-3500 500 trial therapeutics phase 1 therapy cancer phase 2 phase 3
South Star Battery Metals Announces Appointing of Key Team Members for Santa Cruz Graphite Mine Phase 1 Construction and Operations
Published: 2022-02-22 (Crawled : 12:30) - prnewswire.com
ERIC | News | $5.275 -1.59% 14M
|
Electronic Technology
|
| O: 0.0%
H: 1.04%
C: -0.1%
battery als star phase 1 phase 2
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
Published: 2022-02-10 (Crawled : 12:30) - biospace.com/
CVAC | $2.43 -6.54% 590K
|
Health Technology
|
| O: 2.16%
H: 3.12%
C: -4.13%
bone one phase 1 collaboration vaccine influenza
Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
Published: 2022-01-26 (Crawled : 12:30) - biospace.com/
SLN | $22.44 -0.31% 35K
|
Health Technology
|
| O: -0.18%
H: 0.46%
C: -3.89%
sln360 america cardio therapeutics presentation phase 1 cardiology
BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors
Published: 2022-01-24 (Crawled : 12:30) - ir.biolinerx.com
BLRX | $0.591 -7.19% 430K
|
Health Technology
|
| O: -7.25%
H: 3.15%
C: 1.68%
agi-134 solid tumors phase 1 cancer vaccine enroll
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
Published: 2022-01-19 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.089 75K
|
Health Technology
|
| O: 1.33%
H: 1.73%
C: -14.06%
als trial approval stroke phase 1 phase 2 phase 3
Red Pine Updates on its 2022 Phase 1 Drill Program
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
PZG | $0.44 -0.54% 13K
|
Non-Energy Minerals
|
| O: 1.45%
H: 8.26%
C: -1.75%
phase 1 phase 2 phase 3 program
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
Published: 2022-01-05 (Crawled : 12:30) - biospace.com/
MRNA | News S | $107.135 -0.7% 2.1M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
phase 1 vaccine phase 2
UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease
Published: 2021-12-22 (Crawled : 12:30) - globenewswire.com
MREO | $2.82 1.44% 320K
|
Health Technology
|
| O: 0.61%
H: 0.6%
C: -3.01%
mph966 covid-19 respiratory phase 1b trial covid disease phase 1 positive results topline phase 2b alvelestat
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
Published: 2021-12-15 (Crawled : 12:30) - globenewswire.com
TVTX | $5.465 -4.79% 320K
|
Health Technology
|
| O: -3.77%
H: 12.45%
C: 11.01%
ongoing therapeutics phase 1 topline results positive results topline phase 2
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
IMUX | $1.25 0.81% 67K
|
Health Technology
|
| O: -3.49%
H: 1.75%
C: -6.36%
imu-935 trial positive results phase 1 potential positive results
Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting
Published: 2021-12-13 (Crawled : 12:30) - globenewswire.com
MREO | $2.82 1.44% 320K
|
Health Technology
|
| O: -6.16%
H: 0.0%
C: 0.0%
phase 1b trial phase 1 syndros biomarkers phase 2b alvelestat
NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancer
Published: 2021-12-10 (Crawled : 12:30) - biospace.com/
NEO | $13.92 -1.7% 180K
|
Health Services
|
| O: -0.61%
H: 0.0%
C: 0.0%
genomics genomic phase 1 cancer phase 2
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
Published: 2021-12-10 (Crawled : 12:30) - biospace.com/
MRNA | News S | $107.135 -0.7% 2.1M
|
Health Technology
|
| O: -17.85%
H: 0.0%
C: 0.0%
phase 1 positive vaccine phase 2 phase 3
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.185 -5.2% 4.2M
|
Health Technology
|
| O: 7.46%
H: 0.31%
C: -12.81%
ocu400 new drug fda application gene therapy drug trial fda acceptance phase 1 therapy retina
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.